compounded tirzepatide ending 🚨 FDA Moves to Permanently Shut Down GLP-1s The FDA is taking steps to eliminate large-scale compounding of GLP-1 medications like semaglutide and tirzepatide, signaling a major shift in how these What is the latest update

Their independent effects on the gastrointestinal system warrant consideration when used concurrently

The real story is not so simple

The FDA documented over 520 adverse event reports related to compounded semaglutide as of April 2025

The twice-weekly injections, once super intimidating for someone notoriously terrified of needles, have become routine

the second study estimated disease resolution to be 51.5%

Additionally, high patient awareness, advanced healthcare infrastructure, and major pharmaceutical presence, along with direct-to-consumer and telehealth models, are enhancing nationwide access to GLP-1 therapies